Darunavir (DRV)
Sponsors
Tibotec Pharmaceuticals, Ireland, International Maternal Pediatric Adolescent AIDS Clinical Trials Group, ViiV Healthcare, Janssen Scientific Affairs, LLC, University College, London
Conditions
HIV InfectionHIV InfectionsHealthyHuman Immunodeficiency Virus - Type 1Infection, Human Immunodeficiency Virus
Phase 1
TMC114-TiDP3-C176 - A Study in Healthy Volunteers Investigating the Bioequivalence Between Two Commercially Available 400-mg Tablets to One New 800-mg Tablet of Darunavir (DRV) in the Presence of Low-dose Ritonavir Under Fed and Fasted Conditions
CompletedNCT01308658
Start: 2011-01-31End: 2011-05-31Updated: 2014-02-06
DDI Study of BMS-663068 With Etravirine (ETR) and/or Darunavir (DVR) + Ritonavir (RTV)
CompletedNCT02063360
Start: 2014-02-01End: 2014-05-13Updated: 2017-08-08
Study to Evaluate the Relative Bioavailability of Fixed-dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) as a Whole Tablet, as a Split Tablet, and as Crushed Tablet in Healthy Adult Participants
CompletedNCT02984852
Start: 2016-12-31End: 2017-02-28Updated: 2025-02-03
Phase 3
A Study to Compare Effectiveness and Safety of Darunavir/Ritonavir (DRV/Rtv) 800mg/100mg Once Daily Versus DRV/Rtv 600mg/100mg Twice Daily in Early Treatment-Experienced HIV-1 Infected Patients (ODIN)
CompletedNCT00524368
Start: 2007-10-31End: 2011-10-31Updated: 2013-02-15
An Adaptive Platform Trial for Evaluation of Novel Treatment Regimens in Children and Adolescents With HIV in Africa
Not yet recruitingNCT07792096
Start: 2026-11-01End: 2029-12-01Target: 800Updated: 2026-08-28